Prostate Cancer Diagnostics Market - Top Companies and Manufacturers

  • Report ID: 6683
  • Published Date: Nov 13, 2024
  • Report Format: PDF, PPT

Companies Dominating the Prostate Cancer Diagnostics Landscape

    Leading companies operating in the prostate cancer diagnostics market include Abbott Laboratories, GE Healthcare Technologies Inc., Glycanostics Ltd., AdvaCare Pharma, Beckman Coulter, Inc., Becton, Dickinson and Company, bioMérieux, and F. Hoffmann-La Roche Ltd. Major players are investing in research and development, expanding partnerships, and focusing on product launches to strengthen their market presence, especially as demand for precision medicine grows. Furthermore, these players are making investments in research and development, further expanding the series of partnerships, focusing on product launches, and strengthening their presence in the market. 

    For example, Proteomedix AG and Blue Water Biotech Inc. merged in December 2023 to form Onconetix Inc., which integrates products for prostate cancer diagnosis and therapy. This trend in the industry reflects the consolidation and collaboration to realize comprehensive diagnostic portfolios. The enlarged capabilities the merger has brought to Onconetix Inc. speak volumes about the competitive outlook that sees increasing interest in expanding product offerings by companies to leverage their synergies by entering alliances. Such moves by players address diverse needs within prostate cancer diagnostics for early detection and to yield better patient care outcomes.

    Here are some leading players in the prostate cancer diagnostics market:

    • Abbott Laboratories
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AdvaCare Pharma
    • Beckman Coulter, Inc.  
    • Becton, Dickinson and Company
    • BIOMÉRIEUX
    • F. Hoffmann-La Roche Ltd.
    • GE Healthcare Technologies Inc.
    • Glycanostcs Ltd.
    • Healgen
    • KOELIS
    • Metamark Genetics, Inc.
    • miR Scientific
    • Myriad Genetics, Inc.
    • Proteomedix
    • Siemens Healthineers AG

Browse Key Market Insights with Data Illustration:

In the News

  • In September 2024, Cleveland Diagnostics, Inc. relaunched its A PSA on PSA campaign for Prostate Cancer Awareness Month to encourage downloads of a discussion guide from PSAonPSA.com, aimed at enhancing patient-doctor conversations. For each download, Cleveland Diagnostics will donate to ZERO Prostate Cancer, with ZERO matching all donations throughout the month.
  • In July 2024, DELFI Diagnostics secured an equity investment from the Merck Global Health Innovation Fund to expedite the development of its AI-driven fragmentomics platform for cancer screening. This partnership aims to enhance diagnostic capabilities and improve cancer detection methodologies.
  • In May 2024, Quest Diagnostics announced the separation of PathAI's digital pathology laboratory to sharpen its focus on artificial intelligence integration. This strategic shift is intended to accelerate the adoption of AI technologies within Quest's operations, bolstering its digital pathology capabilities and improving diagnostic accuracy.

Author Credits:  Radhika Pawar


  • Report ID: 6683
  • Published Date: Nov 13, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The prostate cancer diagnostics market size is USD 5 billion in 2024.

The global prostate cancer diagnostics market size is valued at US 5 billion in 2024 and is anticipated to surpass USD 19.4 billion by the end of 2037, rising at a CAGR of 11% over the forecast period, i.e., 2025-2037.

Key players in the market include Abbott Laboratories, GE Healthcare Technologies Inc., Glycanostcs Ltd., AdvaCare Pharma, Beckman Coulter, Inc., Becton, Dickinson and Company, BIOMÉRIEUX, and F. Hoffmann-La Roche Ltd.

The diagnostics tests segment is anticipated to hold a leading share during the forecast period.

North America is anticipated to dominate the industry with a share of 34.5% during the forecast period.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample